volume 8, issue 1, P54-68 2015
DOI: 10.15283/ijsc.2015.8.1.54
View full text
|
Sign up to set email alerts
|
Share

Abstract: Mesenchymal stem cells (MSCs) have rapidly been applied in a broad field of immune-mediated disorders since the first successful clinical use of MSCs for treatment of graft-versus-host disease. Despite the lack of supporting data, expectations that MSCs could potentially treat most inflammatory conditions led to rushed application and development of commercialized products. Today, both pre-clinical and clinical studies present mixed results for MSC therapy and the discrepancy between expected and actual effica…

Expand abstract